已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Efficacy of Liposomal Bupivacaine and Bupivacaine Hydrochloride vs Bupivacaine Hydrochloride Alone as a Periarticular Anesthetic for Patients Undergoing Knee Replacement

医学 布比卡因 麻醉 可视模拟标度 不利影响 随机对照试验 局部麻醉剂 骨关节炎 外科 患者满意度 内科学 病理 替代医学
作者
Thomas W. Hamilton,Ruth Knight,Jamie R. Stokes,Ines Rombach,Cushla Cooper,Loretta Davies,Susan Dutton,Karen Barker,Jonathan Cook,Sarah E Lamb,David W. Murray,Lisa Poulton,Ariel Wang,Louise Strickland,Bernard van Duren,José Leal,David Beard,Hemant Pandit,Kirti Mohalkar,Simon Jones
出处
期刊:JAMA Surgery [American Medical Association]
卷期号:157 (6): 481-481 被引量:22
标识
DOI:10.1001/jamasurg.2022.0713
摘要

Importance

More than half of patients who undergo knee replacement surgery report substantial acute postoperative pain.

Objective

To evaluate the efficacy and cost-effectiveness of periarticular liposomal bupivacaine for recovery and pain management after knee replacement.

Design, Setting, and Participants

This multicenter, patient-blinded, pragmatic, randomized clinical superiority trial involved 533 participants at 11 institutions within the National Health Service in England. Adults undergoing primary unilateral knee replacement for symptomatic end-stage osteoarthritis were enrolled between March 29, 2018, and February 29, 2020, and followed up for 1 year after surgery. Follow-up was completed March 1, 2021. A per-protocol analysis for each coprimary outcome was performed in addition to the main intention-to-treat analysis.

Interventions

Two hundred sixty-six milligrams of liposomal bupivacaine admixed with 100 mg of bupivacaine hydrochloride compared with 100 mg of bupivacaine hydrochloride alone (control) administered by periarticular injection at the time of surgery.

Main Outcome and Measures

The coprimary outcomes were Quality of Recovery 40 (QoR-40) score at 72 hours and pain visual analog scale (VAS) score area under the curve (AUC) from 6 to 72 hours. Secondary outcomes included QoR-40 and mean pain VAS at days 0 (evening of surgery), 1, 2, and 3; cumulative opioid consumption for 72 hours; functional outcomes and quality of life at 6 weeks, 6 months, and 1 year; and cost-effectiveness for 1 year. Adverse events and serious adverse events up to 12 months after randomization were also assessed.

Results

Among the 533 participants included in the analysis, the mean (SD) age was 69.0 (9.7) years; 287 patients were women (53.8%) and 246 were men (46.2%). Baseline characteristics were balanced between study groups. There was no difference between the liposomal bupivacaine and control groups in QoR-40 score at 72 hours (adjusted mean difference, 0.54 [97.5% CI, −2.05 to 3.13];P = .64) or the pain VAS score AUC at 6 to 72 hours (−21.5 [97.5% CI, −46.8 to 3.8];P = .06). Analyses of pain VAS and QoR-40 scores demonstrated only 1 statistically significant difference, with the liposomal bupivacaine arm having lower pain scores the evening of surgery (adjusted difference −0.54 [97.5% CI, −1.07 to −0.02];P = .02). No difference in cumulative opioid consumption and functional outcomes was detected. Liposomal bupivacaine was not cost-effective compared with the control treatment. No difference in adverse or serious adverse events was found between the liposomal bupivacaine and control groups.

Conclusions and Relevance

This study found no difference in postoperative recovery or pain associated with the use of periarticular liposomal bupivacaine compared with bupivacaine hydrochloride alone in patients who underwent knee replacement surgery.

Trial Registration

isrctn.com Identifier:ISRCTN54191675
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
地泽万物发布了新的文献求助10
刚刚
LaffiteElla发布了新的文献求助10
刚刚
wanci应助hanleiharry1采纳,获得10
1秒前
2秒前
在水一方应助摸摸采纳,获得10
3秒前
FashionBoy应助Lu采纳,获得10
3秒前
Xw发布了新的文献求助10
3秒前
4秒前
HZ发布了新的文献求助10
4秒前
6秒前
congenialboy发布了新的文献求助10
7秒前
桐桐应助标致的问晴采纳,获得10
10秒前
研究牛王发布了新的文献求助10
10秒前
nito完成签到,获得积分10
10秒前
12秒前
12秒前
15秒前
15秒前
15秒前
16秒前
17秒前
Lu发布了新的文献求助10
17秒前
西哥完成签到 ,获得积分10
18秒前
摸摸完成签到,获得积分20
19秒前
19秒前
20秒前
猪猪hero应助hanleiharry1采纳,获得10
21秒前
dd发布了新的文献求助10
22秒前
摸摸发布了新的文献求助10
22秒前
肃肃其羽完成签到 ,获得积分10
22秒前
Owen应助研究牛王采纳,获得10
23秒前
24秒前
Rondab应助鞑靼采纳,获得10
25秒前
李健的小迷弟应助chang采纳,获得10
25秒前
三井库里完成签到,获得积分10
26秒前
zplease完成签到,获得积分10
26秒前
26秒前
sycsyc完成签到,获得积分10
27秒前
29秒前
30秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989811
求助须知:如何正确求助?哪些是违规求助? 3531927
关于积分的说明 11255560
捐赠科研通 3270706
什么是DOI,文献DOI怎么找? 1805035
邀请新用户注册赠送积分活动 882181
科研通“疑难数据库(出版商)”最低求助积分说明 809190